Articles tagged with Cancer Patients
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers found that two orphan receptor proteins, ERRbeta short and long forms, exert anti-cancer effects on glioblastoma cells when activated by DY131. The short form stops DNA replication, while the long form prevents cell division if DNA is already replicated.
A study published in the British Journal of General Practice found that GPs often do not refer patients for cancer investigations due to concerns about raising patient anxiety. Researchers suggest that GPs should consider discussing cancer possibilities with more openness and involve patients in the decision-making process.
A study by the University of Hawaii Cancer Center found nearly 30% of Hawaiian teens had tried e-cigarettes, with 17% using them only. The rate is three times higher than previously reported US studies. E-cigarette manufacturers' aggressive marketing and wide availability may contribute to this trend.
Researchers at Ohio State University found that patterns of molecules called long noncoding RNAs can predict response to chemotherapy and overall survival in older patients with acute myeloid leukemia. The study identified a group of 48 lncRNAs associated with survival, allowing for personalized treatment approaches.
The study found that Herceptin significantly improved 10-year survival from 75 percent to 84 percent when added to chemotherapy. Additionally, the 10-year disease-free survival rate increased from 62 percent to 74 percent with the addition of trastuzumab.
A study found that one-third of Hawaiian adolescents have tried e-cigarettes, with half having never used another tobacco product. E-cigarette users ranked somewhere between never-smokers and dual-users in terms of risk factors for smoking cigarettes.
A recent study published in Nature Communications sheds light on chromosome segregation and its impact on cancer development. Researchers discovered that mutations in the BubR1 protein can cause cancer by disrupting correct chromosomal passage.
Myriad Genetics announced new studies on its myRisk Hereditary Cancer test, detecting 105% more mutations than conventional BRCA testing. The test also showed promising results in triple negative breast cancer (TNBC) by predicting response to platinum-based therapy. Additionally, the company's BRACAnalysis molecular diagnostic test sig...
A recent study published in the Annals of Otology, Rhinology & Laryngology found that the pulsed-KTP laser treatment developed at Massachusetts General Hospital (MGH) is as effective as traditional approaches in curing patients' tumors while preserving vocal quality. The treatment has shown a high success rate of 96% among patients wit...
A study found that medical residency applicants are linguistically diverse, but their languages do not match those of the US population with limited English proficiency. The most common languages among applicants were Spanish, Hindi, French, Urdu, and Arabic.
Delayed cancer diagnoses are often caused by limitations in scientific knowledge and the delivery of healthcare, not poor professional performance. Despite this, policy initiatives focusing on GP referral times may be ineffective. Researchers advocate for better information about diagnostic challenges to improve diagnosis and care.
A phase 1 trial of ipilimumab, an immune checkpoint blocker, found clinical benefit in 45.4% of relapsed transplant patients, with notable responses in Hodgkin lymphoma and myelodysplastic syndrome. The six-month survival rate was 65%, with four patients remaining on treatment.
A study by Ohio State University researchers found that patients treated at highly-experienced radiation oncology centers had better survival rates and fewer cancer recurrences compared to those treated at less experienced centers. The study analyzed data from 470 patients treated with radiation therapy between 2002-2005.
A study at MD Anderson Cancer Center found PRM-151 to be well-tolerated in patients with advanced myelofibrosis, showing encouraging trends in clinical and histologic aspects of the disease. The therapy demonstrated reduced bone marrow fibrosis and improved hematologic parameters, suggesting potential for further development.
A Dartmouth study found that hookah smoking increased the probability of trying cigarette smoking over two years by 19%. Hookah and snus use are associated with later cigarette smoking in non-cigarette smoking adolescents and young adults. The study highlights the need for FDA regulation to restrict manufacturers' ability to flavor, pa...
A phase 2 multicenter trial of ABT-199 found encouraging results in patients with relapsed or resistant acute myelogenous leukemia, with five patients achieving eradication and several more experiencing stable disease. The oral inhibitor targets the BCL-2 protein, which is linked to resistance and poor prognosis in AML patients.
Studies presented at the ASH Annual Meeting show that immunotherapy drugs pembrolizumab and nivolumab are producing dramatic responses in Classical Hodgkin lymphoma patients. These results are promising for patients with few treatment options left, highlighting the potential of immunotherapies to work in various types of cancer.
Improvements in cancer survival mean half of all people diagnosed today will survive at least 10 years, compared to a quarter 40 years ago. However, cancers like lung, stomach, and pancreatic cancer remain extremely challenging to treat.
Scientists from Queen Mary University of London have developed a new therapy for advanced bladder cancer, showing significant tumor shrinkage in patients. The treatment, MPDL3280A, has been given breakthrough therapy designation status by the US FDA and has promising results in a phase one clinical trial.
A promising immunotherapy drug, MPDL3280A, shows improved efficacy in patients whose immune cells initially attack cancer but are shut down by PD-L1. Researchers found that tumor expression of PD-L1 in surrounding immune cells is a key indicator of response to the treatment.
A two-year study by the Stand Up To Cancer - Cancer Research Institute Immunology Translational Research Dream Team found that pembrolizumab removes PD-1, freeing up immune cells to kill cancer cells. The study validated a pathway to determine patient responsiveness and anticipated better drug combinations for more patients with melanoma.
Researchers found that metformin use was associated with a 23% decrease in mortality compared to other treatments, and may have therapeutic benefits for certain types of cancer, including breast, colorectal, lung, and prostate cancers.
The CONCORD-2 study shows extreme variations in 5-year cancer survival estimates among countries, with some countries achieving high survival rates for certain cancers. Improvements are seen in developed countries and South America, but deficiencies remain in developing countries.
Researchers at University of Cincinnati have found a Food and Drug Administration-approved therapy effective in treating older and African American patients with non-small cell lung cancer. The study suggests that gefitinib improves quality of life and outcomes for this subgroup of patients, who often face limited treatment options.
The investigational drug AG-120 has demonstrated 'extremely promising' early phase 1 clinical trial results for patients with acute myeloid leukemia (AML) harboring IDH1 mutations. This finding builds on previous phase 1 results of a related drug, AG-221, and offers hope for the treatment of this high-risk population.
CPRIT awards UTSW faculty $22.5 million for groundbreaking research into leukemia, liver cancer, and anti-cancer immunotherapy, aiming to drive innovative therapies and better care for cancer patients. The grants will support investigations targeting promising new discoveries in cancer and commercial development.
A multi-centre clinical trial suggests that a combination of three targeted drugs may be more effective than one drug for certain patients with advanced BRAF-mutated colorectal cancer. The treatment, which includes encorafenib, cetuximab, and alpelisib, showed improved efficacy and extended progression-free survival in patients.
Patients with B-cell Non-Hodgkin lymphomas and advanced solid tumors have responded to the new drug E7438, a histone methyltransferase inhibitor. The drug has shown anti-tumor effects in four patients with refractory lymphoma and one patient with a malignant rhabdoid tumor, indicating potential for personalized medical therapy.
A $7.6 million grant supports the validation of molecular tests for early detection of colorectal cancer, aiming to reduce mortality rates. The international Dream Team will focus on developing a blood test to identify patients who can benefit from chemotherapy after surgery.
Patients with advanced papillary kidney cancer respond well to a combination of bevacizumab and erlotinib, with excellent response rates and long-lasting results. The treatment shows promise for patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) who have poor prognosis.
A phase I trial of AG-120, an oral inhibitor of mutant IDH1, has shown clinical activity in patients with advanced acute myeloid leukaemia (AML) and the IDH1 mutation. The drug reduced 2-HG levels to normal, allowing cells to mature into normal functioning cells.
Researchers at Cancer Research UK have identified over 400 areas of hidden faults in the human genome, which could conceal cancer-causing gene mutations. These 'blind spots' are difficult to detect using current gene-reading technology, highlighting opportunities for new diagnostic tests and treatments.
Researchers found that older patients with Alzheimer's or cancer were less likely to receive intensive procedures at the end of life. In contrast, black patients in high-hospital-intensity regions were more likely to undergo these procedures.
Researchers at NUS and their collaborators developed a novel scoring scheme that predicts the ability of cancer cells to spread. The system monitors epithelial-mesenchymal transition (EMT) mechanism, a key process in metastasis, and has shown good correlation with previously published EMT signatures.
A collaboration between St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and Institut Curie-Inserm identified frequent mutations in genes STAG2 and TP53 that define a subtype of Ewing sarcoma associated with reduced survival. The study provides critical insights into the genetic changes that d...
A novel medical-imaging technology called TexRAD has been shown to enable early diagnosis of bowel-cancer patients not responding to standard cancer therapy. The technology analyzes the texture of tumors, distinguishing patients with good prognosis from those with poor prognosis.
A University of Colorado Cancer Center study found that TAK-733, a next-gen melanoma drug, exhibited anti-cancer activity in 10 out of 11 patient tumor samples grown in mice. The drug showed significant shrinkage in tumors up to 100%, regardless of BRAF mutation status.
A pooled analysis of five cohort studies found that smoking before first cancer diagnosis increases risk of developing a second smoking-related cancer. Smoking survivors have up to a 5-fold higher risk of developing a second primary smoking-associated cancer compared to non-smokers.
A new study reveals that informed bladder cancer patients are more motivated to quit smoking, which can prolong their lives. Physicians can significantly impact this by educating patients about the link between smoking and their disease.
Researchers found that higher volume hospital and surgeon volume are associated with fewer post-operative complications and improved overall survival for bladder cancer patients. The study aims to identify processes and interactions leading to better outcomes, which could inform improvements in care at lower volume hospitals.
A new device has been developed to visualize and differentiate between cancer cells in the bloodstream, enabling a more focused understanding of tumour properties. This technology shows promise for better diagnosis and improved patient outcomes by identifying aggressive tumours and metastatic disease.
Researchers discovered that bisphosphonates can inhibit cancer spread in some women with breast cancer by attaching to calcifications in tumors and being devoured by immune cells. This finding could lead to new, more effective ways of using these drugs to treat certain cancers.
The incidence of colorectal cancer in people under 50 has increased, while those over 50 have seen a decline. The study found that the CRC incidence rate declined overall between 1975 and 2010, but rose among young adults, with the biggest increase seen in patients 20-34 years old.
Incidence rates of colon and rectal cancers among 20-34 year olds are projected to increase by 90% and 124.2%, respectively, by 2030. Lifestyle factors such as obesity and lack of physical activity contribute to the rising trend, while screening efforts in older patients have led to a decline in incidence rates among those over 50.
Patients with emergency-diagnosed lung cancer reported difficulties in seeing their general practitioner (GP), including lack of confidence and fear of diagnosis. Nearly half of the patients delayed seeking medical attention for over 12 weeks, highlighting the need for improved patient education and rapid-access diagnostic clinics.
Dr. John Carpten, Deputy Director of TGen, receives AACR Distinguished Lectureship for his work on cancer health disparities in minority populations. He will deliver a keynote lecture on November 9 at the AACR conference.
A trial revealed that patients with a specific type of esophageal cancer who received the lung cancer drug gefitinib survived longer, with some patients living up to six months beyond their initial treatment. The drug has shown promise as a targeted treatment for this disease.
A new trial has shown the Cytosponge test to be an accurate and safe way of diagnosing Barrett's Oesophagus. The test involves swallowing a sponge on a string and has been proven to be more effective than traditional endoscopy for detecting the condition.
A recent study published in The Journal of Experimental Medicine found that obesity can lead to lethal inflammation in response to certain anti-cancer therapies. This suggests that preclinical studies on young mice may not accurately predict outcomes in older patients, who are more likely to be overweight and develop cancer.
A study by Ben-Gurion University of the Negev found that preclinical oncology courses increased students' interest in specializing in oncology and empathy for cancer patients. The research suggests a need for medical schools to include such curriculum to develop communication skills and sensitivity towards death and dying.
A team of researchers has made a breakthrough in early diagnosis of invasive cancers, detecting lung cancer in patients at risk through circulating cancer cells in their bloodstream. This method could enable early surgical intervention and potentially improve patient survival.
The Cancer Health Literacy Study developed an evaluation tool called the Cancer Health Literacy Test (CHLT)-30 to measure cancer health literacy along a continuum. The study found that 18% of cancer patients have limited CHL, with an overrepresentation of African-American, undereducated and low-income patients.
A comprehensive review of 19,000 scientific papers identified more than 800 cancer-specific biomarkers that could lead to a single blood test for early detection of many types of cancer. The study aims to develop a screening test from a single blood sample for multiple cancer types.
Researchers developed a new strategy to detect bladder cancer using CD47, a protein that signals the immune system not to attack. The technique improves bladder cancer detection, guides precise surgery, and reduces unnecessary biopsies, increasing patients' quality of life.
A recent study published in Psycho-Oncology highlights the need for well-designed trials to determine the effectiveness of phone counseling interventions for cancer survivors. The research found that while some studies showed significant improvement, the results were not robust across multiple end points or studies.
Two studies found pediatric breast cancer patients experienced longer time between diagnosis and treatments, often diagnosed at later stages. Pediatric colon cancer patients had lower five-year survival rates than adults due to more aggressive tumors and treatments.
Rare cancer patients face scarce clinical evidence due to conventional trial methodologies requiring large patient numbers. The European Organisation for Research and Treatment of Cancer recommends alternative study designs and collaborative networking.
Researchers found that erlotinib, a targeted drug for advanced-stage lung cancer, can increase the aggressiveness of tumors in early-stage patients, leading to accelerated growth and decreased survival rates. The study suggests combining an EGFR inhibitor with a Notch inhibitor may overcome this effect.
Breast cancer patients taking brand name aromatase inhibitors had higher discontinuation rates and nonadherence compared to those on generic AIs. Higher copayments of $15-$30 per month were also linked to discontinued use.
UT Southwestern Medical Center is expanding its genetic screening program to 22 North Texas counties, serving underserved populations with HBOC and Lynch syndrome risk. The new grant will connect patients with genetic specialists through telemedicine, increasing accessibility and reducing transportation costs.